[Ip-health] Divide & Conquer: A look inside the EU pharmaceutical industry lobby

Joao Carapinha joao at carapinha.com
Wed Mar 28 08:45:22 PDT 2012

Dear Colleagues:

Here's an interesting report on pharmaceutical industry lobbying activities
in Europe.
*HAI Europe / CEO latest report Divide & Conquer: A look inside the EU
pharmaceutical industry lobby*

*"Executive Summary*
*This report surveyed the entries made by pharmaceutical companies and
their representatives *
*in the EU’s lobby Transparency Register to find out how much the industry
claimed to spend on *
*lobbying. According to these findings, the pharmaceutical industry lobby
is spending more than *
*€40 million annually to influence decision making in the European Union
(EU) – of which nearly *
*half is spent by drug manufacturers on in-house lobbyists. *
*Results from this study show that many pharmaceutical companies lobbying
the European *
*Commission on legislation fail to declare their activities to the
Register. As registration to the *
*Transparency Register is voluntary, many pharmaceutical companies choose
not to declare *
*their expenditures. If recorded properly, expenditure on lobbying
activities by the industry could *
*be shown to be as high as €91 million annually. *
*Civil society organisations active on EU medicines issues, on the other
hand, spend a combined *
*€3.4 million per year. With the immense disparity between the affluence of
public interest groups *
*and the industrial lobby, it becomes even more difficult to level the
policy playing field.*
*This estimate is more comparable to pharma’s lobby footprint in the USA,
where the *
*pharmaceutical manufacturing sector has reportedly spent about €85.5
million ($115 million *
*USD) in lobbying the American government in 2011. The report estimates
that 220 lobbyists are*
*active in the EU on behalf of the pharmaceutical industry, which pales in
comparison to nearly *
*1500 industry lobbyists documented in the US in 2011. Clear and enforced
reporting rules in the *
*US yield a more accurate picture of pharma’s lobby contingent in America
as compared to the *

João L. Carapinha

Pharmaceutical Policy Analyst

*Join me on:*


More information about the Ip-health mailing list